
## Augustin Amour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5922127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Organ-on-a-chip: current gaps and future directions. Biochemical Society Transactions, 2022, 50, 665-673.	3.4	17
2	The 5-Phosphatase SHIP2 Promotes Neutrophil Chemotaxis and Recruitment. Frontiers in Immunology, 2021, 12, 671756.	4.8	4
3	Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. International Journal of COPD, 2021, Volume 16, 1621-1636.	2.3	13
4	Organ-on-chip applications in drug discovery: an end user perspective. Biochemical Society Transactions, 2021, 49, 1881-1890.	3.4	22
5	Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. Journal of Medicinal Chemistry, 2021, 64, 13780-13792.	6.4	3
6	Converging TLR9 and PI3Kgamma signaling induces sterile inflammation and organ damage. Scientific Reports, 2019, 9, 19085.	3.3	10
7	An investigation of the antiâ€inflammatory effects and a potential biomarker of <scp>PI</scp> 3Kδ inhibition in <scp>COPD</scp> T cells. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 932-940.	1.9	9
8	Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 961-973.	5.6	125
9	Evolution of a Novel, Orally Bioavailable Series of PI3KδInhibitors from an Inhaled Lead for the Treatment of Respiratory Disease. Journal of Medicinal Chemistry, 2016, 59, 7239-7251.	6.4	22
10	Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase Ĩ´for the Treatment of Respiratory Disease. Journal of Medicinal Chemistry, 2015, 58, 7381-7399.	6.4	118
11	Functional capacity of alveolar neutrophils in acute respiratory distress syndrome. Lancet, The, 2014, 383, S64.	13.7	1
12	Targeting phosphoinositide 3â€kinase l̂´ for the treatment of respiratory diseases. Annals of the New York Academy of Sciences, 2013, 1280, 35-39.	3.8	60
13	Targeting phosphoinositide 3-kinase δ for allergic asthma. Biochemical Society Transactions, 2012, 40, 240-245.	3.4	42
14	Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates. Analytical Biochemistry, 2009, 384, 56-67.	2.4	13
15	TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4. Journal of Biological Chemistry, 2007, 282, 20991-20998.	3.4	63
16	A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics, 2006, 6, 2112-2120.	2.2	45
17	ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. International Journal of Cancer, 2006, 118, 263-273.	5.1	84
18	Continuous real-time measurement of tumor necrosis factor-α converting enzyme activity on live cells. Laboratory Investigation, 2005, 85, 1440-1448.	3.7	24

AUGUSTIN AMOUR

#	Article	IF	CITATIONS
19	Synthesis and evaluation of Î-Lactams (Piperazones) as elastase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 387-389.	2.2	30
20	Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's β-secretase. Journal of Cell Biology, 2003, 163, 97-107.	5.2	175
21	Heparan sulphate binds the aspartic protease β-Secretase and regulates cleavage of APP. Biochemical Society Transactions, 2002, 30, A69-A69.	3.4	0
22	Discovery of Further Pyrrolidinetrans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151). Journal of Medicinal Chemistry, 2002, 45, 3878-3890.	6.4	53
23	The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Letters, 2002, 520, 102-106.	2.8	33
24	The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Letters, 2002, 524, 154-158.	2.8	128
25	Enzyme Accessibility and Solid Supports: Which Molecular Weight Enzymes Can Be Used on Solid Supports? An Investigation Using Confocal Raman Microscopy. Chemistry - A European Journal, 2002, 8, 3769.	3.3	73
26	Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2002, 16, 220-228.	1.5	50
27	The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase—GW311616A a development candidate. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 895-898.	2.2	52
28	Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2. Journal of Biological Chemistry, 2000, 275, 14046-14055.	3.4	195
29	Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus. Journal of Biological Chemistry, 2000, 275, 41358-41363.	3.4	112
30	The in vitro activity of ADAMâ€10 is inhibited by TIMPâ€1 and TIMPâ€3. FEBS Letters, 2000, 473, 275-279.	2.8	351
31	Inhibition of the Metalloproteinase Domain of Mouse TACE. Annals of the New York Academy of Sciences, 1999, 878, 728-731.	3.8	13
32	Design and Synthesis of Hydrazinopeptides and Their Evaluation as Human Leukocyte Elastase Inhibitors. Journal of Medicinal Chemistry, 1998, 41, 4833-4843.	6.4	43
33	TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters, 1998, 435, 39-44.	2.8	547
34	Stereoselective synthesis and inhibitor properties towards human leucocyte elastase of chiral β-peptidyl trifluoromethyl alcohols Tetrahedron: Asymmetry, 1994, 5, 1099-1110.	1.8	21
35	Synthesis and protease atalyzed hydrolysis of a novel hydrazinopeptide. International Journal of Peptide and Protein Research, 1994, 43, 297-304.	0.1	16